[1]肖何,王阁,王东,等.非小细胞肺癌血浆EGFR突变与肿瘤标志物水平的关系[J].第三军医大学学报,2013,35(14):1520-1523.
 Xiao He,Wang Ge,Wang Dong,et al.Relationship between plasma EGFR mutation and serum levels of tumor markers in non-small cell lung cancer[J].J Third Mil Med Univ,2013,35(14):1520-1523.
点击复制

非小细胞肺癌血浆EGFR突变与肿瘤标志物水平的关系(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
35卷
期数:
2013年第14期
页码:
1520-1523
栏目:
论著
出版日期:
2013-07-30

文章信息/Info

Title:
Relationship between plasma EGFR mutation and serum levels of tumor markers in non-small cell lung cancer
作者:
肖何王阁王东杨镇洲杨宇馨
第三军医大学大坪医院野战外科研究所肿瘤中心
Author(s):
Xiao He Wang Ge Wang Dong Yang Zhenzhou Yang Yuxin
Cancer Center, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, 400042, China
关键词:
非小细胞肺癌表皮生长因子血浆游离DNA突变肿瘤标志物
Keywords:
non-small cell lung cancer epidermal growth factor receptor plasma free DNA mutation tumor markers
分类号:
R730.43;R734.2
文献标志码:
A
摘要:
目的      探讨非小细胞肺癌外周血游离DNA样本EGFR突变率与临床基线特征和血清肿瘤标志物表达水平的关系。      方法      收集本院确诊为非小细胞肺癌166例。利用PCR和变性高效液相色谱法分析EGFR19和21外显子突变。其中89例同时利用多肿瘤标志物蛋白芯片检测系统检测癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原153(CA153)等血清肿瘤标志物,分析突变率与临床基线特征和肿瘤标志物表达水平的关系。      结果      166例非小细胞肺癌中,EGFR总突变率19.9%。女性突变率显著高于男性(P=0.037)。腺癌突变率高于其他组织学类型,但未达到显著水平(P=0.096)。CEA、CA153中高表达患者EGFR突变率显著高于低表达者(P=0.048,P=0.017),CA199高表达患者仅有高于中低表达者的趋势(P=0.093)。多变量Logistic分析表明,组织学类型为腺癌,CA153、CEA中、高表达与EGFR突变率相关。      结论      对于晚期非小细胞肺癌,血浆EGFR突变率与血清肿瘤标志物表达水平明显相关。其标志物水平可作为进一步判断EGFR突变优势群体的因素。
Abstract:
Objective      To investigate the relationship of epidermal growth factor receptor (EGFR) mutation in plasma free DNA with clinical characteristics of baseline as well as serum expression levels of tumor markers in patients with advanced non-small cell lung cancer (NSCLC).       Methods      One hundred and sixty-six patients with pathologically confirmed NSCLC hospitalized in our department from June 2011 to June 2012 were enrolled in this study. Their clinical data and peripheral blood samples were collected. PCR and denaturing high-performance liquid chromatography (DHPLC) were performed to detect EGFR mutations in exons 19 and 21 in the free DNA from the 166 samples of peripheral blood. The serum levels of 12 tumor makers, such as carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125, CA153 and so on, were analyzed with multi-tumor markers protein biochip detective system in 89 patients simultaneously. The relationships of EGFR mutation with the patients’ clinical characteristics at baseline and with corresponding serum levels of tumor makers were analyzed.       Results      The total mutation rate of EGFR was 19.9% in 166 NSCLC patients, with that in females significantly higher than that in males (P=0.037). Though the rate was higher in adenocarcinoma than the other histological types, no significant difference was seen among them (P=0.096). The mutation rate was significantly higher in the patients with moderate and high serum levels of CEA and CA153 than those with mild expression levels (P=0.048,  P=0.017). However, the rate was also high in those with high expression of CA199 than those with moderate and mild expression though without significant difference (P=0.093). Multivariable Logistic regression showed that adenocarcinoma, and moderate and high expression of CEA and CA153 were significantly correlated with EGFR mutation.       Conclusion      The mutation rate of EGFR is significantly related with the serum levels of tumor markers in late NSCLC, and the serum levels can be a potential indicator to determine the EGFR mutation.

参考文献/References:

肖何, 王阁, 王东, 等. 非小细胞肺癌血浆EGFR突变与肿瘤标志物水平的关系[J].第三军医大学学报,2013,35(14):1520-1523.

相似文献/References:

[1]杨庆羚,刘翩,王斌,等.EGFR-TKIs治疗晚期非小细胞肺癌并发间质性肺炎4例报告并文献复习[J].第三军医大学学报,2012,34(20):2060.
 Yang Qingling,Liu Pian,Wang Bin,et al.Interstitial pneumonia in EGFR-TKIs-treated non-small-cell lung cancer: report of 4 cases and review of the literature[J].J Third Mil Med Univ,2012,34(14):2060.
[2]斯晓燕,张力.西妥昔单抗联合化疗一线治疗非小细胞肺癌20例临床观察[J].第三军医大学学报,2012,34(20):2063.
 Si Xiaoyan,Zhang Li.Outcomes of cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer[J].J Third Mil Med Univ,2012,34(14):2063.
[3]罗虎,罗丹,宫亮,等.联合CIK细胞与化疗对比单纯化疗治疗中晚期非小细胞肺癌的Meta分析[J].第三军医大学学报,2012,34(20):2119.
[4]张瑞萍,吴继华,黄英武,等.循环肿瘤细胞检测指导老年非小细胞肺癌个体化治疗1例[J].第三军医大学学报,2012,34(22):2248.
[5]闫霞,曹官铭,王导新.吉西他滨联合卡铂治疗老年非小细胞肺癌的临床评价[J].第三军医大学学报,2007,29(19):1913.
 YAN Xia,CAO Guan-min,WANG Dao-xin.Gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients[J].J Third Mil Med Univ,2007,29(14):1913.
[6]闵发胜,陈正堂.人非小细胞肺癌与外周血淋巴细胞表达LRP的相关性研究[J].第三军医大学学报,2007,29(17):1699.
 MIN Fa-sheng,CHEN Zheng-tang.Correlation between expression of lung resistance-related protein in non-small cell lung cancer and that in peripheral blood lymphocytes[J].J Third Mil Med Univ,2007,29(14):1699.
[7]高娟,饶进军,吴少瑜,等.丁酸钠与顺铂联用对非小细胞性肺癌细胞生长的抑制作用[J].第三军医大学学报,2007,29(11):1066.
 GAO Juan,RAO Jin-jun,WU Shao-yu,et al.Combination of sodium butyrate and cisplatin has antiproliferative effects on non-small lung cancer cell line[J].J Third Mil Med Univ,2007,29(14):1066.
[8]王炼炼,丘彦,幸贵邦.表皮生长因子促进小鼠未成熟卵母细胞体外成熟的实验研究[J].第三军医大学学报,2007,29(22):2179.
 WANG Lian-lian,QIU Yan,XING Gui-bang.Epidermal growth factor improves in vitro maturation of immature mouse oocytes[J].J Third Mil Med Univ,2007,29(14):2179.
[9]李咏梅,陈金龙,杨海文,等.融合蛋白EGF-TCS的纯化及体外靶向杀伤肿瘤细胞的研究[J].第三军医大学学报,2007,29(13):1316.
 LI Yong-mei,CHEN Jin-long,YANG Hai-wen,et al.Purification of EGF-TCS recombinant fusion protein and its targeting action on human tumor cells in vitro[J].J Third Mil Med Univ,2007,29(14):1316.
[10]郑顺利,杨庆生,马小红.非小细胞肺癌患者纵隔淋巴结和外周血中MUC1基因的检测及意义[J].第三军医大学学报,2006,28(24):2472.
[11]蒋娟,易亭伍,张瑜,等.非小细胞肺癌的肿瘤干细胞与非肿瘤干细胞中表皮生长因子受体基因异质性的研究[J].第三军医大学学报,2012,34(20):2039.
 Jiang Juan,Yi Tingwu,Zhang Yu,et al.Genetic heterogeneity of EGFR in cancer and non-cancer stem cells from non-small cell lung cancer[J].J Third Mil Med Univ,2012,34(14):2039.

更新日期/Last Update: 2013-07-10